Clinical Trial Update: FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. [Phase 3]

View source ↗

Summary

This Phase 3 trial tests FOLFOXIRI plus bevacizumab with or without atezolizumab as first-line treatment for pMMR and IC-High metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Colorectal Cancer | Phase 3 | Status: RECRUITING